PriceTargets.com logo

Liquidia - LQDA Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $27.13
  • Forecasted Upside: 69.64%
  • Number of Analysts: 9
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 6 Buy Ratings
  • 2 Strong Buy Ratings
$15.99 As of 05/13/2025 05:00 PM ET
▲ +0.24 (1.52%)

This chart shows the closing price for LQDA by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Liquidia Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for LQDA and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for LQDA

Analyst Price Target is $27.13
▲ +69.64% Upside Potential
This price target is based on 9 analysts offering 12 month price targets for Liquidia in the last 3 months. The average price target is $27.13, with a high forecast of $36.00 and a low forecast of $20.00. The average price target represents a 69.64% upside from the last price of $15.99.

This chart shows the closing price for LQDA for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 9 contributing investment analysts is to buy stock in Liquidia. This rating has held steady since December 2024, when it changed from a Moderate Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/21/2023
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
2/19/2024
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
5/19/2024
  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
8/17/2024
  • 2 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
11/15/2024
  • 2 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
2/13/2025
  • 2 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
4/14/2025
  • 2 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
5/14/2025

Latest Recommendations

  • 2 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
5/12/2025Needham & Company LLCReiterated RatingBuy ➝ Buy$25.00 ➝ $25.00
5/12/2025HC WainwrightReiterated RatingBuy ➝ Buy$29.00 ➝ $29.00
5/9/2025Raymond JamesBoost TargetStrong-Buy ➝ Strong-Buy$27.00 ➝ $29.00
5/5/2025ScotiabankReiterated RatingOutperform ➝ Outperform
5/5/2025ScotiabankBoost TargetSector Outperform ➝ Sector Outperform$34.00 ➝ $36.00
4/10/2025Needham & Company LLCReiterated RatingBuy ➝ Buy$25.00 ➝ $25.00
3/20/2025ScotiabankReiterated RatingOutperform ➝ Outperform
3/20/2025ScotiabankBoost TargetSector Outperform ➝ Sector Outperform$30.00 ➝ $34.00
3/20/2025Needham & Company LLCBoost TargetBuy ➝ Buy$19.00 ➝ $25.00
3/20/2025HC WainwrightReiterated RatingBuy ➝ Buy$29.00 ➝ $29.00
1/9/2025Needham & Company LLCReiterated RatingBuy ➝ Buy$19.00 ➝ $19.00
12/20/2024Wells Fargo & CompanyInitiated CoverageOverweight$20.00
11/14/2024HC WainwrightReiterated RatingBuy ➝ Buy$29.00 ➝ $29.00
11/14/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$19.00 ➝ $19.00
10/16/2024ScotiabankInitiated CoverageSector Outperform$30.00
10/3/2024Lifesci CapitalInitiated CoverageOutperform$30.00
10/2/2024Lifesci CapitalUpgradeStrong-Buy
8/20/2024HC WainwrightLower TargetBuy ➝ Buy$32.00 ➝ $29.00
8/20/2024Bank of AmericaLower TargetBuy ➝ Buy$24.00 ➝ $23.00
8/19/2024BTIG ResearchLower TargetBuy ➝ Buy$29.00 ➝ $25.00
8/19/2024Raymond JamesUpgradeOutperform ➝ Strong-Buy
8/19/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$25.00 ➝ $25.00
8/16/2024Raymond JamesInitiated CoverageOutperform ➝ Outperform$27.00 ➝ $27.00
8/8/2024Needham & Company LLCLower TargetBuy ➝ Buy$28.00 ➝ $25.00
7/18/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$28.00 ➝ $28.00
7/10/2024HC WainwrightReiterated RatingBuy ➝ Buy$32.00 ➝ $32.00
6/25/2024OppenheimerInitiated CoverageMarket Perform
6/3/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$28.00 ➝ $28.00
5/15/2024HC WainwrightReiterated RatingBuy ➝ Buy$32.00
5/15/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$28.00
4/10/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$28.00
4/1/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$28.00
3/14/2024HC WainwrightBoost TargetBuy ➝ Buy$16.00 ➝ $32.00
3/13/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$28.00
2/21/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$28.00
1/5/2024Needham & Company LLCBoost TargetBuy ➝ Buy$18.00 ➝ $28.00
12/21/2023LADENBURG THALM/SH SHBoost TargetBuy ➝ Buy$15.00 ➝ $30.00
12/21/2023Bank of AmericaBoost TargetBuy ➝ Buy$13.00 ➝ $15.00
12/21/2023WedbushReiterated RatingUnderperform ➝ Underperform$3.00
11/9/2023WedbushReiterated RatingOutperform$3.00
11/8/2023Needham & Company LLCReiterated RatingBuy ➝ Buy$18.00
9/26/2023Needham & Company LLCReiterated RatingBuy ➝ Buy$18.00
8/14/2023WedbushReiterated RatingUnderperform ➝ Underperform$3.00
8/11/2023HC WainwrightReiterated RatingBuy ➝ Buy$16.00
8/10/2023Needham & Company LLCReiterated RatingBuy ➝ Buy$18.00
7/31/2023Needham & Company LLCReiterated RatingBuy ➝ Buy$18.00
7/25/2023Needham & Company LLCReiterated RatingBuy ➝ Buy$18.00
7/6/2023BTIG ResearchLower Target$20.00 ➝ $18.00
6/30/2023WedbushReiterated RatingUnderperform$3.00
4/19/2023Needham & Company LLCReiterated RatingBuy$18.00
3/17/2023Needham & Company LLCBoost TargetBuy$16.00 ➝ $18.00
2/3/2023Needham & Company LLCReiterated RatingBuy$16.00
11/9/2022WedbushReiterated RatingUnderperform$3.00
9/19/2022WedbushReiterated RatingUnderperform$3.00
9/6/2022BTIG ResearchBoost Target$20.00
9/1/2022Needham & Company LLCBoost TargetBuy$12.00 ➝ $16.00
9/1/2022WedbushDowngradeNeutral ➝ Underperform$4.00 ➝ $3.00
7/22/2022LADENBURG THALM/SH SHInitiated CoverageBuy$15.00
7/20/2022BTIG ResearchBoost TargetBuy$14.00 ➝ $17.00
5/31/2022BTIG ResearchInitiated CoverageBuy$14.00
5/26/2022Bank of AmericaInitiated CoverageBuy$12.00
2/3/2022HC WainwrightBoost TargetBuy$6.00 ➝ $16.00
1/10/2022Needham & Company LLCBoost TargetBuy$8.00 ➝ $12.00
1/7/2022WedbushReiterated RatingHold$6.00
11/8/2021Needham & Company LLCBoost TargetPositive ➝ Buy$5.00 ➝ $8.00
3/24/2021HC WainwrightReiterated RatingBuy$6.00
3/23/2021Needham & Company LLCLower TargetBuy$6.00 ➝ $5.00
12/4/2020HC WainwrightInitiated CoverageBuy$6.00
11/30/2020WedbushReiterated RatingHold$4.00
11/20/2020WedbushDowngradeOutperform ➝ Neutral$20.00 ➝ $4.00
10/15/2020WedbushLower TargetOutperform$38.00 ➝ $20.00
7/7/2020Needham & Company LLCReiterated RatingBuy$24.00
7/7/2020WedbushReiterated RatingBuy$38.00
6/12/2020WedbushReiterated RatingBuy$41.00
(Data available from 5/14/2020 forward)

News Sentiment Rating

1.05 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 10 very positive mentions
  • 22 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/16/2024
  • 7 very positive mentions
  • 14 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/15/2024
  • 12 very positive mentions
  • 5 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
12/15/2024
  • 6 very positive mentions
  • 6 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
1/14/2025
  • 10 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/13/2025
  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/15/2025
  • 13 very positive mentions
  • 18 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
Mentions as of
4/14/2025
  • 31 very positive mentions
  • 14 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
Mentions as of
5/14/2025

Current Sentiment

  • 31 very positive mentions
  • 14 positive mentions
  • 3 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

Negative

Positive

Very Positive

Liquidia logo
Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company also offers Remodulin, a treprostinil administered through continuous intravenous and subcutaneous infusion. The company also a license agreement with Pharmosa Biopharm Inc to develop and commercialize L606, an inhaled sustained-release formulation of Treprostinil for the treatment of PAH and PH-ILD. Liquidia Corporation was founded in 2004 and is headquartered in Morrisville, North Carolina.
Read More

Today's Range

Now: $15.99
Low: $15.44
High: $16.17

50 Day Range

MA: $14.25
Low: $11.99
High: $16.12

52 Week Range

Now: $15.99
Low: $8.26
High: $16.81

Volume

883,974 shs

Average Volume

1,005,917 shs

Market Capitalization

$1.37 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.24

Frequently Asked Questions

What sell-side analysts currently cover shares of Liquidia?

The following Wall Street research analysts have issued reports on Liquidia in the last twelve months: Bank of America Co., BTIG Research, HC Wainwright, Lifesci Capital, Needham & Company LLC, Oppenheimer Holdings Inc., Raymond James, Scotiabank, and Wells Fargo & Company.
View the latest analyst ratings for LQDA.

What is the current price target for Liquidia?

0 Wall Street analysts have set twelve-month price targets for Liquidia in the last year. Their average twelve-month price target is $27.13, suggesting a possible upside of 69.6%. Scotiabank has the highest price target set, predicting LQDA will reach $36.00 in the next twelve months. Wells Fargo & Company has the lowest price target set, forecasting a price of $20.00 for Liquidia in the next year.
View the latest price targets for LQDA.

What is the current consensus analyst rating for Liquidia?

Liquidia currently has 1 hold rating, 6 buy ratings and 2 strong buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe LQDA will outperform the market and that investors should add to their positions of Liquidia.
View the latest ratings for LQDA.

What other companies compete with Liquidia?

Other companies that are similar to Liquidia include Inari Medical, Inspire Medical Systems, iRhythm Technologies, Bausch + Lomb and TransMedics Group. Learn More about companies similar to Liquidia.

How do I contact Liquidia's investor relations team?

Liquidia's physical mailing address is 419 DAVIS DRIVE SUITE 100, MORRISVILLE NC, 27560. The company's listed phone number is (919) 328-4400 and its investor relations email address is [email protected]. The official website for Liquidia is www.liquidia.com. Learn More about contacing Liquidia investor relations.